Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
21.40
+0.40 (1.90%)
Oct 29, 2025, 11:27 AM EDT - Market open
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 261.00K CHF in the quarter ending June 30, 2025, with 6.53% growth. This brings the company's revenue in the last twelve months to 764.00K, down -12.28% year-over-year. In the year 2024, Oculis Holding AG had annual revenue of 686.00K, down -22.31%.
Revenue (ttm)
764.00K CHF
Revenue Growth
-12.28%
P/S Ratio
1,156.03
Revenue / Employee
15,592 CHF
Employees
49
Market Cap
1.12B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
OCS News
- 14 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 15 days ago - Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 - GlobeNewsWire
- 23 days ago - Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy - GlobeNewsWire
- 4 weeks ago - Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities - GlobeNewsWire
- 5 weeks ago - Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS - GlobeNewsWire
- 7 weeks ago - Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 - GlobeNewsWire
- 2 months ago - Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences - GlobeNewsWire
- 2 months ago - Oculis to Participate in Upcoming September Investor Conferences - GlobeNewsWire